425 related articles for article (PubMed ID: 27253658)
1. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
[TBL] [Abstract][Full Text] [Related]
2. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Ufer M; Kelsh D; Schoedel KA; Dingemanse J
Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
[TBL] [Abstract][Full Text] [Related]
4. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
Landry I; Hall N; Aluri J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):365-373. PubMed ID: 35749758
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
[TBL] [Abstract][Full Text] [Related]
6. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
[TBL] [Abstract][Full Text] [Related]
7. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
[TBL] [Abstract][Full Text] [Related]
8. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
Born S; Gauvin DV; Mukherjee S; Briscoe R
Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
[TBL] [Abstract][Full Text] [Related]
9. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.
Levy-Cooperman N; Schoedel KA; Chakraborty B; Blum D; Cheng H
Epilepsy Behav; 2016 Aug; 61():63-71. PubMed ID: 27315134
[TBL] [Abstract][Full Text] [Related]
10. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.
Schoedel KA; Stockis A; Sellers EM
Epilepsy Behav; 2018 Jan; 78():194-201. PubMed ID: 29153631
[TBL] [Abstract][Full Text] [Related]
11. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning.
Bland H; Li X; Mangin E; Yee KL; Lines C; Herring WJ; Gillespie G
J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):414-420. PubMed ID: 34181362
[TBL] [Abstract][Full Text] [Related]
12. Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users.
Landry I; Hall N; Alur J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):374-382. PubMed ID: 35748777
[TBL] [Abstract][Full Text] [Related]
13. Suvorexant: scientifically interesting, utility uncertain.
Keks NA; Hope J; Keogh S
Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
[TBL] [Abstract][Full Text] [Related]
14. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
Sun H; Yee KL; Gill S; Liu W; Li X; Panebianco D; Mangin E; Morrison D; McCrea J; Wagner JA; Troyer MD
J Psychopharmacol; 2015 Nov; 29(11):1159-69. PubMed ID: 26464455
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
[TBL] [Abstract][Full Text] [Related]
16. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.
Yee KL; McCrea J; Panebianco D; Liu W; Lewis N; Cabalu T; Ramael S; Wrishko RE
Clin Drug Investig; 2018 Jul; 38(7):631-638. PubMed ID: 29705869
[TBL] [Abstract][Full Text] [Related]
18. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
[TBL] [Abstract][Full Text] [Related]
19. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
20. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
Sun H; Kennedy WP; Wilbraham D; Lewis N; Calder N; Li X; Ma J; Yee KL; Ermlich S; Mangin E; Lines C; Rosen L; Chodakewitz J; Murphy GM
Sleep; 2013 Feb; 36(2):259-67. PubMed ID: 23372274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
